GLYC - New data from GlycoMimetics highlights the efficacy Rivipansel in Vaso-Occlusive Crisis in sickle cell disease

GlycoMimetics (NASDAQ:GLYC) announces new data supporting the statistically significant effects of rivipansel in acute vaso-occlusive crisis in patients with sickle cell disease.The data from the OLE efficacy analysis, presented at ASH, together with more extensive data from the previously-reported, post-hoc analysis of the RESET trial, indicated the achievement of statistically significant improvements in primary and key secondary endpoints.Additionally, the open-label study demonstrated statistically significant effects of early treatment with rivipansel on the time to discharge and time for discontinuation of intravenous opioids across both the all-ages and pediatric populations.The Phase 3 RESET trial conducted by Pfizer (NYSE:PFE), GlycoMimetics’ former collaborator, did not meet its primary or key secondary efficacy endpoints in 2019. The new efficacy data from a post hoc analysis of rivipansel were published in June 2020. “While we fully expect that additional clinical data will be required to achieve registration for rivipansel, we plan to continue interactions with the

For further details see:

New data from GlycoMimetics highlights the efficacy Rivipansel in Vaso-Occlusive Crisis in sickle cell disease